{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:45:16Z","timestamp":1774309516172,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s11523-024-01032-5","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T13:02:39Z","timestamp":1707742959000},"page":"223-235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4047-2585","authenticated-orcid":false,"given":"Margherita","family":"Rimini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Loi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario Domenico","family":"Rizzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Pressiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Vivaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Gusmaroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Garajova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Lucchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Schirripa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Cornara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Rossari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Vitiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Amadeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Persano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria Matilde","family":"Piva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Balsano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Salani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Pircher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Cascinu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Niger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Zavattari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Casadei-Gardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"issue":"12","key":"1032_CR1","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1080\/17474124.2021.1991313","volume":"15","author":"M Rimini","year":"2021","unstructured":"Rimini M, Puzzoni M, Pedica F, Silvestris N, Fornaro L, Aprile G, et al. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol. 2021;15(12):1367\u201383. https:\/\/doi.org\/10.1080\/17474124.2021.1991313.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"6","key":"1032_CR2","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1053\/j.gastro.2018.01.033","volume":"154","author":"J Wu","year":"2018","unstructured":"Wu J, Yang S, Xu K, Ding C, Zhou Y, Fu X, et al. Patterns and trends of liver cancer incidence rates in Eastern and Southeastern Asian countries (1983\u20132007) and predictions to 2030. Gastroenterology. 2018;154(6):1719-28.e5. https:\/\/doi.org\/10.1053\/j.gastro.2018.01.033.","journal-title":"Gastroenterology"},{"issue":"1","key":"1032_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","volume":"71","author":"P Bertuccio","year":"2019","unstructured":"Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71(1):104\u201314. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.013.","journal-title":"J Hepatol"},{"key":"1032_CR4","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1053\/j.gastro.2016.11.048","volume":"152","author":"D Sia","year":"2017","unstructured":"Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152:745\u201361.","journal-title":"Gastroenterology"},{"issue":"2","key":"1032_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jhep.2019.11.020","volume":"72","author":"V Mazzaferro","year":"2020","unstructured":"Mazzaferro V, Gorgen A, Roayaie S, DrozDitBusset M, Sapisochin G. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):364\u201377. https:\/\/doi.org\/10.1016\/j.jhep.2019.11.020.","journal-title":"J Hepatol"},{"issue":"14","key":"1032_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med"},{"key":"1032_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.506","author":"A Vogel","year":"2022","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, ESMO Guidelines Committee, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340.  https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506.","journal-title":"Ann Oncol"},{"issue":"9","key":"1032_CR8","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.3390\/jcm9092854","volume":"9","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Kapacee Z, Breeze M, Bell C, Belcher D, Staiger H, et al. Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers. J Clin Med. 2020;9(9):2854. https:\/\/doi.org\/10.3390\/jcm9092854.","journal-title":"J Clin Med"},{"key":"1032_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ejca.2022.08.026","volume":"175","author":"M Rimini","year":"2022","unstructured":"Rimini M, Loi E, Fabregat-Franco C, Burgio V, Lonardi S, Niger M, et al. Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters. Eur J Cancer. 2022;175:299\u2013310. https:\/\/doi.org\/10.1016\/j.ejca.2022.08.026.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1032_CR10","doi-asserted-by":"publisher","first-page":"18775","DOI":"10.1038\/s41598-022-22543-z","volume":"12","author":"M Rimini","year":"2022","unstructured":"Rimini M, Fabregat-Franco C, Burgio V, Lonardi S, Niger M, Scartozzi M, et al. Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma. Sci Rep. 2022;12(1):18775. https:\/\/doi.org\/10.1038\/s41598-022-22543-z.","journal-title":"Sci Rep"},{"key":"1032_CR11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ejca.2022.05.004","volume":"171","author":"M Rimini","year":"2022","unstructured":"Rimini M, Macarulla T, Burgio V, Lonardi S, Niger M, Scartozzi M, et al. Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. Eur J Cancer. 2022;171:232\u201341. https:\/\/doi.org\/10.1016\/j.ejca.2022.05.004.","journal-title":"Eur J Cancer"},{"issue":"9","key":"1032_CR12","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","volume":"47","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003\u201310. https:\/\/doi.org\/10.1038\/ng.3375.","journal-title":"Nat Genet"},{"key":"1032_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","author":"DY Oh","year":"2022","unstructured":"Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. NEJM Evid. 2022. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid."},{"key":"1032_CR14","doi-asserted-by":"publisher","unstructured":"Valle JW, Qin S, Antonuzzo L, Tougeron D, Lee C, et al. Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC). Ann Oncol. 2022;33(Suppl_9):S1454\u201384.  https:\/\/doi.org\/10.1016\/annonc\/annonc1123.","DOI":"10.1016\/annonc\/annonc1123"},{"issue":"23","key":"1032_CR15","doi-asserted-by":"publisher","first-page":"00727","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"S0140\u20136736","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;S0140\u20136736(23):00727\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet"},{"issue":"13","key":"1032_CR16","doi-asserted-by":"publisher","first-page":"i404","DOI":"10.1093\/bioinformatics\/bty232","volume":"34","author":"W Zhang","year":"2018","unstructured":"Zhang W, Flemington EK, Zhang K. Driver gene mutations based clustering of tumors: methods and applications. Bioinformatics. 2018;34(13):i404\u201311. https:\/\/doi.org\/10.1093\/bioinformatics\/bty232.","journal-title":"Bioinformatics"},{"issue":"6127","key":"1032_CR17","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546\u201358. https:\/\/doi.org\/10.1126\/science.1235122.","journal-title":"Science"},{"issue":"2","key":"1032_CR18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell. 2018;173(2):321-37.e10. https:\/\/doi.org\/10.1016\/j.cell.2018.03.035.","journal-title":"Cell"},{"issue":"Suppl 4","key":"1032_CR19","doi-asserted-by":"publisher","first-page":"LBA490","DOI":"10.1200\/JCO.2023.41.3_suppl.LBA490","volume":"41","author":"RT Shroff","year":"2023","unstructured":"Shroff RT, Guthrie KA, Scott AJ, et al. SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J Clin Oncol. 2023;41(Suppl 4):LBA490. https:\/\/doi.org\/10.1200\/JCO.2023.41.3_suppl.LBA490.","journal-title":"J Clin Oncol"},{"key":"1032_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/bcr3670","volume":"16","author":"JA Watkins","year":"2014","unstructured":"Watkins JA, Irshad S, Grigoriadis A, Tutt AN. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 2014;16:211.","journal-title":"Breast Cancer Res"},{"key":"1032_CR21","doi-asserted-by":"publisher","first-page":"814e9","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner N, Tutt A, Ashworth A. Hallmarks of \u2018BRCAness\u2019 in sporadic cancers. Nat Rev Canc. 2004;4:814e9.","journal-title":"Nat Rev Canc"},{"key":"1032_CR22","first-page":"551","volume":"34","author":"F Muggia","year":"2014","unstructured":"Muggia F, Safra T. \u2018BRCAness\u2019 and its implications for platinum action in gynecologic cancer. Anticancer Res. 2014;34:551\u20136.","journal-title":"Anticancer Res"},{"issue":"7035","key":"1032_CR23","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913\u20137. https:\/\/doi.org\/10.1038\/nature03443.","journal-title":"Nature"},{"issue":"3","key":"1032_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","volume":"122","author":"MM Wattenberg","year":"2020","unstructured":"Wattenberg MM, Asch D, Yu S, O\u2019Dwyer PJ, Domchek SM, Nathanson KL, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 2020;122(3):333\u20139. https:\/\/doi.org\/10.1038\/s41416-019-0582-7.","journal-title":"Br J Cancer"},{"issue":"4","key":"1032_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1903387.","journal-title":"N Engl J Med"},{"issue":"4","key":"1032_CR26","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","volume":"60","author":"MJ O'Connor","year":"2015","unstructured":"O\u2019Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547\u201360. https:\/\/doi.org\/10.1016\/j.molcel.2015.10.040.","journal-title":"Mol Cell"},{"issue":"9","key":"1032_CR27","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.it.2014.06.003","volume":"35","author":"G Chatzinikolaou","year":"2014","unstructured":"Chatzinikolaou G, Karakasilioti I, Garinis GA. DNA damage and innate immunity: links and trade-offs. Trends Immunol. 2014;35(9):429\u201335. https:\/\/doi.org\/10.1016\/j.it.2014.06.003.","journal-title":"Trends Immunol"},{"issue":"7","key":"1032_CR28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","volume":"7","author":"KW Mouw","year":"2017","unstructured":"Mouw KW, Goldberg MS, Konstantinopoulos PA, D\u2019Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7(7):675\u201393. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0226.","journal-title":"Cancer Discov"},{"issue":"20","key":"1032_CR29","doi-asserted-by":"publisher","first-page":"7504","DOI":"10.3390\/ijms21207504","volume":"21","author":"C Nastasi","year":"2020","unstructured":"Nastasi C, Mannarino L, D\u2019Incalci M. DNA damage response and immune defense. Int J Mol Sci. 2020;21(20):7504. https:\/\/doi.org\/10.3390\/ijms21207504.","journal-title":"Int J Mol Sci"},{"issue":"5795","key":"1032_CR30","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pag\u00e8s C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960\u20134. https:\/\/doi.org\/10.1126\/science.1129139.","journal-title":"Science"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01032-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01032-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01032-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T10:51:24Z","timestamp":1711363884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01032-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1032"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01032-5","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"4 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Monica Niger received travel expenses from AstraZeneca, speaker honoraria from Accademia della Medicina and Incyte; honoraria from Sandoz, Medpoint SRL, Incyte, and Servier for editorial collaboration; and consultant honoraria from EMD Serono, Basilea Pharmaceutica, Incyte, MSD Italia, Servier, Astrazeneca, and Taiho. TP: Swedish Orpahn Biovitrum AB, Ability Pharmaceuticals SL, Aptitude Health, AstraZeneca, Basilea Pharma, Baxter, BioLineRX Ltd, Celgene, Eisai, Ellipses, Genzyme, Got It Consulting SL, Hirslanden\/GITZ, Imedex, Incyte, Ipsen Bioscience , Inc, Janssen, Lilly. Marketing Farmac\u00e9utico & Investigaci\u00f3n Cl\u00ednica, S.L, MDS, Medscape, Novocure, Paraxel, PPD Development, Polaris, QED Therapeutics, Roche Farma, Sanofi-Aventis, Servier, Scilink Comunicaci\u00f3n Cient\u00edfica SC, Surface Oncology, and Zymeworks. Tiziana Pressiani received\/reports consulting fees from Bayer, Ipsen, and Astra Zeneca; institutional research funding from Roche, Bayer, and Astra Zeneca; and travel accommodations from Roche. Lorenza Rimassa declares consulting\/advisory roles for AstraZeneca, Basilea, Bayer, BMS, Eisai, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; honoraria for lectures from AstraZeneca, Bayer, BMS, Eisai, Incyte, Ipsen, Merck Serono, Roche, and Servier; travel expenses from AstraZeneca; and research funding (to institution) from Agios, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, and Zymeworks. Sara Lonardi reports research funding (to institution) from Amgen, Astellas, Astra Zeneca, Bayer, Bristol-Myers Squibb, Daichii Sankyo, Hutchinson, Incyte, Merck Serono, Mirati, MSD, Pfizer, Roche, and Servier; personal honoraria as an invited speaker from Amgen, Bristol-Myers Squibb, Incyte, GSK, Lilly, Merck Serono, MSD, Pierre-Fabre, Roche, and Servier; and participation in advisory boards for Amgen, Astellas, Astra Zeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, GSK, Incyte, Lilly, Merck Serono, MSD, Servier, and Takeda. Lorenzo Fornaro reports personal honoraria as an invited speaker from Incyte, Bristol Myers Squibb and Lilly; research funding (to institution) from MSD, Bristol Myers Squibb, AstraZeneca, Incyte, BeiGene, Astellas, Daiichi Sankyo, and Roche; and participation in advisory boards for MSD, AstraZeneca, Incyte, Taiho, Servier, Daiichi Sankyo, and Lilly. Margherita Rimini, Eleonora Loi, Mario Domenico Rizzato, Caterina Vivaldi, Eleonora Gusmaroli, Lorenzo Antonuzzo, Erika Martinelli, Ingrid Garajova, Guido Giordano,\u00a0Jessica Lucchetti, Marta Schirripa, Noemi Cornara, Federico Rossari, Francesco Vitiello, Elisabeth Amadeo, Mara Persano, Vittoria Matilde Piva, Rita Balsano, Francesca Salani, Chiara Pircher, Stefano Cascinu, Mario Scartozzi, Patrizia Zavattari, Andrea Casadei-Gardini have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest\/Competing Interests"}},{"value":"The ethics review board of each institutional hospital approved the present study. This study was performed in line with the principles of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent for treatment was obtained for all patients.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data are available on request from the authors.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conception and design: EL, MR, PZ, AC-G; acquisition of data (acquired and managed patients): all authors. analysis and interpretation of data: EL, MR, PZi, AC-G; writing, review, and\/or revision of the manuscript: EL, MR, PZ, AC-G; final approval of manuscript: all authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}